Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 2;221(2):218-222.
doi: 10.1093/infdis/jiz450.

High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia

Belinda V Chihota  1   2 , Gilles Wandeler  2   3 , Roma Chilengi  1 , Lloyd Mulenga  4   5 , Raymond T Chung  6 , Debika Bhattacharya  7 , Mathias Egger  2   8 , Michael J Vinikoor  1   4   9
Affiliations

High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia

Belinda V Chihota et al. J Infect Dis. .

Abstract

Among 284 human immunodeficiency virus (HIV)-hepatitis B virus (HBV) coinfected adults starting tenofovir-based antiretroviral therapy (ART) in Zambia, median baseline CD4+ count was 202 cells/mm3 and 41.6% were hepatitis B e-antigen positive. Within 2 years of therapy, 29 (10.2%) participants experienced HBV functional cure (confirmed loss of hepatitis B surface antigen). In multivariable analysis, baseline CD4 count <350 cells/mm3, female sex, and lower baseline HBV deoxyribonucleic acid were associated with increased odds of functional cure. Immune recovery during HIV-HBV treatment with ART may drive higher rates of functional cure than during HBV monoinfection treatment. Understanding the mechanisms underlying this phenomenon could inform immunomodulatory therapies for HBV cure.

Keywords: Africa; HBV functional cure; HIV-HBV coinfection; antiretroviral therapy outcomes.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Percentage of human immunodeficiency virus-hepatitis B virus-coinfected patients with hepatitis B surface antigen (HBsAg) loss by 2 years of tenofovir-based therapy, by CD4 count.
See this image and copyright information in PMC

References

    1. Yeo YH, Ho HJ, Yang HI, et al. . Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis. Gastroenterology 2019; 156:635–646.e9. - PubMed
    1. Kim GA, Lim YS, An J, et al. . HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut 2014; 63:1325–32. - PubMed
    1. Gehring AJ. New treatments to reach functional cure: rationale and challenges for emerging immune-based therapies. Best Pract Res Clin Gastroenterol 2017; 31:337–45. - PubMed
    1. Singh KP, Crane M, Audsley J, Avihingsanon A, Sasadeusz J, Lewin SR. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS 2017; 31:2035–52. - PMC - PubMed
    1. Kouamé G-M, Boyd A, Moh R, et al. . Higher mortality despite early antiretroviral therapy in human immunodeficiency virus and hepatitis B virus (HBV)-coinfected patients with high HBV replication. Clin Infect Dis 2018; 66:112–20. - PubMed

Publication types